Antibodies

22 Feb 2008 FDA Grants Accelerated Approval of Avastin in Combination With Paclitaxel Chemotherapy for First-Line Treatment of Advanced HER2-Negative Breast Cancer
22 Feb 2008 Phase II Study of IMC-1121B for Advanced Liver Cancer Commences Patient Enrollment
22 Feb 2008 Abbott Receives FDA Approval for HUMIRA® (Adalimumab) for Polyarticular Juvenile Idiopathic Arthritis
22 Feb 2008 Comparison of AMD Treatments Trials (CATT): Lucentis — Avastin Trial
21 Feb 2008 Antisoma starts phase I clinical trial of AS1409 in renal cancer and melanoma
21 Feb 2008 MorphoSys and Astellas Extend Alliance for Use of HuCAL GOLD to Develop Novel Antibody Therapies
20 Feb 2008 Acceleron Pharma Announces Global Collaboration with Celgene Corporation on ACE-011 Program for Cancer-Related Bone Loss
20 Feb 2008 InNexus Biotechnology Announces Second Preclinical Candidate DXL702 (HER2/neu) Targeting Breast Cancer
19 Feb 2008 Biolex Therapeutics Enters Into Agreement With Merck KGaA for Antibody Optimization
18 Feb 2008 Takeda Discontinues Development of Matuzumab
18 Feb 2008 EUSA Pharma Out-Licenses Preclinical-Stage Human Antibody to GlaxoSmithKline for up to $44 Million Plus Royalties
14 Feb 2008 Second phase III study of Avastin in 1st line metastatic breast cancer meets its primary endpoint
13 Feb 2008 YM BioSciences USA Enrolls First Patient in Phase II Trial of Nimotuzumab in Children with Inoperable, Recurrent Brain Caincer
13 Feb 2008 Raven Announces Completion of Enrollment in the Phase 1/2a Clinical Trial of RAV12 Therapeutic Antibody for the Treatment of Adenocarcinomas
13 Feb 2008 Sanofi-aventis enters into Antibody Agreements with Dyaxand "Phage Display Technology"
12 Feb 2008 MorphoSys Receives CTA Approval to Initiate Phase 1 Clinical Study for MOR103 Program
12 Feb 2008 Thallion Agrees with FDA on a Path Forward for Shigamabs Development Program in the U.S.
11 Feb 2008 2008 is a decisive year for the validation of the asthma target interleukin-13
11 Feb 2008 FDA issues Special Protocol Assessment (SPA) for pivotal Phase III trial with CA9-SCAN
08 Feb 2008 Clinical Experience With Peregrine's Anti-Cancer Agent Bavituximab Presented at Leading Symposium on Anti-Angiogenic Agents
08 Feb 2008 Novel anti-CD20 monoclonal antibody ofatumumab demonstrates anti-tumour responses in patients with relapsed/refractory B-cell chronic lymphocytic leukaemia
07 Feb 2008 Human Genome Sciences and Xencor Announce Genoma Collaboration
07 Feb 2008 InNexus Biotechnology Announces Preliminary Results of Animal Study Comparing Cancer Killing Activity of Its DXL625 (CD20) Treatment for Non-Hodgkin’s Lymphoma With Leading Marketed Product
07 Feb 2008 Biovitrum and Symphogen have Successfully Completed Phase I Clinical Trial with Recombinant Polyclonal Antibody
06 Feb 2008 FDA Agrees to Review Cimzia® File for the Treatment of Rheumatoid Arthritis

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top